SMAD4 anticorps (full length)

N° du produit ABIN7879053

L’anticorps anti-SMAD4 Monoclonal Souris est utilisé pour la détection de SMAD4 dans des échantillons de Humain. Il a été validé pour IHC (p).

Aperçu rapide pour SMAD4 anticorps (full length) (ABIN7879053)

Antigène: SMAD4 (SMAD Family Member 4 (SMAD4))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp SMAD4 est non-conjugé

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Classe de qualité: Carrier-free

Clone: SMAD4-2440

Détail du produit anti-SMAD4 anticorps

Épitope: full length

Fonction: SMAD4 Antibody (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogène: Recombinant full-length human protein was used as the immunogen for the SMAD4 antibody.

Isotype: IgG2a, kappa

Information d'application

Indications d'application: Optimal dilution of the SMAD4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the SMAD4 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur SMAD4

Antigène: SMAD4 (SMAD Family Member 4 (SMAD4))

Autre désignation: SMAD4

Sujet: Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. SMAD4 is absent in approximately 80 % of pancreatic adenocarcinoma, but rarely in endometrial, colorectal, ovarian, lung, breast adenocarcinomas, and malignant melanom. SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients.

UniProt: Q13485

Pathways: Cycle Cellulaire, Chromatin Binding, Autophagy